{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-018148","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.400587+00:00","generated_at":"2026-06-21T13:59:13.327934+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aytu BioPharma receives 180-day Nasdaq extension to May 2023 to regain $1 bid price compliance","bullets":["Nasdaq granted 180-day extension to May 22, 2023 to meet minimum bid price of $1.00 per share.","Stockholders approved reverse stock split up to 1-for-20; board may enact before Oct 4, 2023.","If not compliant by May 22, 2023, Nasdaq will delist common stock; company may appeal.","Failure to regain compliance could lead to delisting; no assurance appeal would succeed.","Extension has no immediate effect on listing or trading under symbol AYTU."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-018148","json":"https://secwatch.observer/filing/0001558370-22-018148.json","markdown":"https://secwatch.observer/filing/0001558370-22-018148.md","text":"https://secwatch.observer/filing/0001558370-22-018148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022018148/0001558370-22-018148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022018148/aytu-20221122x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:59:13.327934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8de184b609841527c83ba1d98c83fe67ed7e8db9","claim":"AYTU BIOPHARMA, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 22, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 22, 2023, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule under the Nasdaq Listing Rules, including enacting a reverse stock split. On October 5, 2022, the Company’s stockholders approved an amendment to its Cer","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022018148/0001558370-22-018148-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}